Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2023

Open Access 01-12-2023 | Review

The role of alternative pre-mRNA splicing in cancer progression

Authors: Sunkyung Choi, Namjoon Cho, Eun-Mi Kim, Kee K. Kim

Published in: Cancer Cell International | Issue 1/2023

Login to get access

Abstract

Alternative pre-mRNA splicing is a critical mechanism that generates multiple mRNA from a single gene, thereby increasing the diversity of the proteome. Recent research has highlighted the significance of specific splicing isoforms in cellular processes, particularly in regulating cell numbers. In this review, we examine the current understanding of the role of alternative splicing in controlling cancer cell growth and discuss specific splicing factors and isoforms and their molecular mechanisms in cancer progression. These isoforms have been found to intricately control signaling pathways crucial for cell cycle progression, proliferation, and apoptosis. Furthermore, studies have elucidated the characteristics and functional importance of splicing factors that influence cell numbers. Abnormal expression of oncogenic splicing isoforms and splicing factors, as well as disruptions in splicing caused by genetic mutations, have been implicated in the development and progression of tumors. Collectively, these findings provide valuable insights into the complex interplay between alternative splicing and cell proliferation, thereby suggesting the potential of alternative splicing as a therapeutic target for cancer.
Literature
1.
2.
Irimia M, Roy SW. Evolutionary convergence on highly-conserved 3 ' Intron Structures in Intron-Poor Eukaryotes and Insights into the ancestral eukaryotic genome. PLOS Genet. 2008;4(8):e1000148.PubMedPubMedCentralCrossRef
3.
Choi S, Cho N, Kim KK. Non-canonical splice junction processing increases the diversity of RBFOX2 splicing isoforms. Int J Biochem Cell Biol. 2022;144:106172.PubMedCrossRef
4.
Choi S, Lee HS, Cho N, Kim I, Cheon S, Park C, et al. RBFOX2-regulated TEAD1 alternative splicing plays a pivotal role in Hippo-YAP signaling. Nucleic Acids Res. 2022;50(15):8658–73.PubMedPubMedCentralCrossRef
5.
Cho N, Joo J, Choi S, Kang BG, Lee AJ, Youn SY, et al. A novel splicing variant of DJ-1 in Parkinson’s disease induces mitochondrial dysfunction. Heliyon. 2023;9(3):e14039.PubMedPubMedCentralCrossRef
6.
Lee S, Jung H, Choi S, Cho N, Kim EM, Kim KK. Intron retention decreases METTL3 expression by inhibiting mRNA export to the cytoplasm. BMB Rep. 2023;56(9):514–9.PubMedPubMedCentralCrossRef
7.
Chan JJ, Zhang B, Chew XH, Salhi A, Kwok ZH, Lim CY, et al. Pan-cancer pervasive upregulation of 3’ UTR splicing drives tumourigenesis. Nat Cell Biol. 2022;24(6):928–39.PubMedPubMedCentralCrossRef
8.
Pan Q, Shai O, Lee LJ, Frey JB, Blencowe BJ. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet. 2008;40(12):1413–5.PubMedCrossRef
9.
10.
11.
12.
Daguenet E, Dujardin G, Valcárcel J. The pathogenicity of splicing defects: mechanistic insights into pre-mRNA processing inform novel therapeutic approaches. EMBO Rep. 2015;16(12):1640–55.PubMedPubMedCentralCrossRef
13.
Kahles A, Lehmann KV, Toussaint NC, Hüser M, Stark SG, Sachsenberg T, et al. Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 patients. Cancer Cell. 2018;34(2):211–24.PubMedPubMedCentralCrossRef
14.
15.
Scully R, Panday A, Elango R, Willis NA. DNA double-strand break repair-pathway choice in somatic mammalian cells. Nat Rev Mol Cell Biol. 2019;20(11):698–714.PubMedPubMedCentralCrossRef
16.
Orth JD, Loewer A, Lahav G, Mitchison TJ. Prolonged mitotic arrest triggers partial activation of apoptosis, resulting in DNA damage and p53 induction. Mol Biol Cell. 2012;23(4):567–76.PubMedPubMedCentralCrossRef
17.
Matthews HK, Bertoli C, de Bruin RAM. Cell cycle control in cancer. Nat Rev Mol Cell Biol. 2022;23(1):74–88.PubMedCrossRef
18.
19.
Wahl MC, Will CL, Lührmann R. The spliceosome: Design Principles of a dynamic RNP machine. Cell. 2009;136(4):701–18.PubMedCrossRef
20.
21.
Denisov SV, Bazykin GA, Sutormin R, Favorov AV, Mironov AA, Gelfand MS, et al. Weak negative and positive selection and the drift load at Splice Sites. Genome Biol Evol. 2014;6(6):1437–47.PubMedPubMedCentralCrossRef
22.
Montemayor EJ, Curran EC, Liao HH, Andrews KL, Treba CN, Butcher SE, et al. Core structure of the U6 small nuclear ribonucleoprotein at 1.7-Å resolution. Nat Struct Mol Biol. 2014;21(6):544–51.PubMedPubMedCentralCrossRef
23.
Barbosa-Morais NL, Irimia M, Pan Q, Xiong HY, Gueroussov S, Lee LJ, et al. The Evolutionary Landscape of Alternative Splicing in Vertebrate Species. Science. 2012;338(6114):1587–93.PubMedCrossRef
24.
Van Nostrand EL, Freese P, Pratt GA, Wang XF, Wei XT, Xiao R, et al. A large-scale binding and functional map of human RNA-binding proteins. Nature. 2020;583(7818):711–9.PubMedPubMedCentralCrossRef
25.
Marasco LE, Kornblihtt AR. The physiology of alternative splicing. Nat Rev Mol Cell Biol. 2023;24(4):242–54.PubMedCrossRef
26.
27.
Ding L, Cao JQ, Lin W, Chen HJ, Xiong XH, Ao HS, et al. The roles of cyclin-dependent kinases in cell-cycle progression and therapeutic strategies in human breast Cancer. Int J Mol Sci. 2020;21(6):1960.PubMedPubMedCentralCrossRef
28.
Collier AE, Spandau DF, Wek RC. Translational control of a human CDKN1A mRNA splice variant regulates the fate of UVB-irradiated human keratinocytes. Mol Biol Cell. 2018;29(1):29–41.PubMedPubMedCentralCrossRef
29.
30.
Petronzelli F, Sollima D, Coppola G, Martini-Neri ME, Neri G, Genuardi M. CDKN2A germline splicing mutation affecting both P16(ink4) and P14(arf) RNA processing in a melanoma/neurofibroma kindred. Genes Chromosom Cancer. 2001;31(4):398–401.PubMedCrossRef
31.
Loo JCY, Liu L, Hao AH, Gao LZ, Agatep R, Shennan M, et al. Germline splicing mutations of CDKN2A predispose to melanoma. Oncogene. 2003;22(41):6387–94.PubMedCrossRef
32.
Zschemisch NH, Liedtke C, Dierssen U, Nevzorova YA, Wüstefeld T, Borlak J, et al. Expression of a cyclin E1 isoform in mice is correlated with the quiescent cell cycle status of hepatocytes in vivo. Hepatology. 2006;44(1):164–73.PubMedCrossRef
33.
Knudsen KE, Diehl JA, Haiman CA, Knudsen ES. Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene. 2006;25(11):1620–8.PubMedCrossRef
34.
Paronetto MP, Cappellari M, Busà R, Pedrotti S, Vitali R, Comstock C, et al. Alternative splicing of the cyclin D1 Proto-Oncogene is regulated by the RNA-Binding protein Sam68. Cancer Res. 2010;70(1):229–39.PubMedCrossRef
35.
Comstock CES, Augello MA, Benito RP, Karch J, Tran TH, Utama FE, et al. Cyclin D1 splice variants: polymorphism, risk, and isoform-specific regulation in prostate Cancer. Clin Cancer Res. 2009;15(17):5338–49.PubMedPubMedCentralCrossRef
36.
Solomon DA, Wang Y, Fox SR, Lambeck TC, Giesting S, Lan Z, et al. Cyclin D1 splice variants - Differential effects on localization, RB phosphorylation, and cellular transformation. J Biol Chem. 2003;278(32):30339–47.PubMedCrossRef
37.
Lu FM, Gladden AB, Diehl JA. An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. Cancer Res. 2003;63(21):7056–61.PubMed
38.
Sun Q, Zhang FX, Wafa K, Baptist T, Pasumarthi KBS. A splice variant of cyclin D2 regulates cardiomyocyte cell cycle through a novel protein aggregation pathway. J Cell Sci. 2009;122(10):1563–73.PubMedCrossRef
39.
Denicourt C, Legault P, McNabb FA, Rassart E. Human and mouse cyclin D2 splice variants: transforming activity and subcellular localization. Oncogene. 2008;27(9):1253–62.PubMedCrossRef
40.
Ellenrieder C, Bartosch B, Lee GYC, Murphy M, Sweeney C, Hergersberg M, et al. The long form of CDK2 arises via alternative splicing and forms an active protein kinase with cyclins a and E. DNA Cell Biol. 2001;20(7):413–23.PubMedCrossRef
41.
Ji XJ, Humenik J, Yang D, Liebhaber SA. PolyC-binding proteins enhance expression of the CDK2 cell cycle regulatory protein via alternative splicing. Nucleic Acids Res. 2018;46(4):2030–44.PubMedCrossRef
42.
Jackson DP, Ting JHH, Pozniak PD, Meurice C, Schleidt SS, Dao A, et al. Identification and characterization of two novel alternatively spliced E2F1 transcripts in the rat CNS. Mol Cell Neurosci. 2018;92:1–11.PubMedPubMedCentralCrossRef
43.
Cates HM, Heller EA, Lardner CK, Purushothaman I, Peña CJ, Walker DM, et al. Transcription factor E2F3a in Nucleus Accumbens affects Cocaine Action via transcription and alternative splicing. Biol Psychiat. 2018;84(3):167–79.PubMedCrossRef
44.
He YW, Armanious MK, Thomas MJ, Cress WD. Identification of E2F-3B, an alternative form of E2F-3 lacking a conserved N-terminal region. Oncogene. 2000;19(30):3422–33.PubMedCrossRef
45.
Leone G, Nuckolls F, Ishida S, Adams M, Sears R, Jakoi L, et al. Identification of a novel E2F3 product suggests a mechanism for determining specificity of repression by rb proteins. Mol Cell Biol. 2000;20(10):3626–32.PubMedPubMedCentralCrossRef
46.
Cygan KJ, Soemedi R, Rhine CL, Profeta A, Murphy EL, Murray MF, et al. Defective splicing of the RB1 transcript is the dominant cause of retinoblastomas. Hum Genet. 2017;136(9):1303–12.PubMedPubMedCentralCrossRef
47.
Bhateja P, Chiu M, Wildey G, Lipka MB, Fu PF, Yang MCL, et al. Retinoblastoma mutation predicts poor outcomes in advanced non small cell lung cancer. Cancer Med. 2019;8(4):1459–66.PubMedPubMedCentralCrossRef
48.
Dehainault C, Michaux D, Pages-Berhouet S, Caux-Moncoutier V, Doz F, Desjardins L, et al. A deep intronic mutation in the RB1 gene leads to intronic sequence exonisation. Eur J Hum Genet. 2007;15(4):473–7.PubMedCrossRef
49.
Valverde JR, Alonso J, Palacios I, Pestana A. RBI gene mutation up-date, a meta-analysis based on 932 reported mutations available in a searchable database. BMC Genet. 2005;6.
50.
Senturk S, Yao Z, Camioloa M, Stilesb B, Rathod T, Walsh AM, et al. p53Ψ is a transcriptionally inactive p53 isoform able to reprogram cells toward a metastatic-like state. Proc Natl Acad Sci U S A. 2014;111(32):E3287–96.PubMedPubMedCentralCrossRef
51.
Miller M, Shirole N, Tian R, Pal D, Sordella R. The evolution of TP53 mutations: from loss-of-function to separation-of-function mutants. J Cancer Biol Res. 2016;4(4):1091.PubMedPubMedCentral
52.
Smeby J, Sveen A, Eilertsen IA, Danielsen SA, Hoff AM, Eide PW, et al. Transcriptional and functional consequences of TP53 splice mutations in colorectal cancer. Oncogenesis. 2019;8:35.PubMedPubMedCentralCrossRef
53.
Pinto EM, Maxwell KN, Halalsheh H, Phillips A, Powers J, MacFarland S, et al. Clinical and functional significance of TP53 exon 4-Intron 4 Splice Junction Variants. Mol Cancer Res. 2022;20(2):207–16.PubMedCrossRef
54.
Shirole NH, Pal D, Kastenhuber ER, Senturk S, Boroda J, Pisterzi P, et al. TP53 exon-6 truncating mutations produce separation of function isoforms with pro-tumorigenic functions. eLife. 2016;5:e17929.PubMedPubMedCentralCrossRef
55.
Dang CV, O’Donnell KA, Zeller KI, Nguyen T, Osthus RC, Li F. The c-Myc target gene network. Semin Cancer Biol. 2006;16(4):253–64.PubMedCrossRef
56.
57.
58.
59.
Zhang H, Fan SJ, Prochownik EV. Distinct roles for MAX protein isoforms in proliferation and apoptosis. J Biol Chem. 1997;272(28):17416–24.PubMedCrossRef
60.
Arsura M, Deshpande A, Hann SR, Sonenshein GE. Variant Max protein, derived by alternative splicing, associates with C-Myc in-vivo and inhibits transactivation. Mol Cell Biol. 1995;15(12):6702–9.PubMedPubMedCentralCrossRef
61.
Mäkelä TP, Koskinen PJ, Vastrik I, Alitalo K. Alternative forms of Max as Enhancers or Suppressors of myc-ras Cotransformation. Science. 1992;256(5055):373–7.PubMedCrossRef
62.
Kemmerer K, Weigand JE. Hypoxia reduces MAX expression in endothelial cells by unproductive splicing. FEBS Lett. 2014;588(24):4784–90.PubMedCrossRef
63.
Ngo T, Corrales A, Bourne T, Elmojahid S, Lam KS, Díaz E. Alternative splicing of MXD3 and its regulation of MXD3 levels in Glioblastoma. Front Mol Biosci. 2019;6:5.PubMedPubMedCentralCrossRef
64.
65.
66.
67.
Furukawa M, Xiong Y. BTB protein keap1 targets antioxidant transcription factor nrf2 for ubiquitination by the cullin 3-Roc1 ligase. Mol Cell Biol. 2005;25(1):162–71.PubMedPubMedCentralCrossRef
68.
Zhang DD, Lo SC, Cross JV, Templeton DJ, Hannink M. Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol Cell Biol. 2004;24(24):10941–53.PubMedPubMedCentralCrossRef
69.
Kobayashi A, Kang MI, Okawa H, Ohtsuji M, Zenke Y, Chiba T, et al. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate for proteasomal degradation of Nrf2. Mol Cell Biol. 2004;24(16):7130–9.PubMedPubMedCentralCrossRef
70.
Cullinan SB, Gordan JD, Jin JO, Harper JW, Diehl JA. The Keap1-BTB protein is an adaptor that bridges Nrf2 to a Cul3-based E3 ligase: oxidative stress sensing by a Cul3-Keap1 ligase. Mol Cell Biol. 2004;24(19):8477–86.PubMedPubMedCentralCrossRef
71.
Hayes JD, McMahon M, Chowdhry S, Dinkova-Kostova AT. Cancer chemoprevention mechanisms mediated through the Keap1-Nrf2 pathway. Antioxid Redox Signal. 2010;13(11):1713–48.PubMedCrossRef
72.
Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, et al. An Nrf2 small maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun. 1997;236(2):313–22.PubMedCrossRef
73.
74.
Nguyen T, Sherratt PJ, Pickett CB. Regulatory mechanisms controlling gene expression mediated by the antioxidant response element. Annu Rev Pharmacol Toxicol. 2003;43:233–60.PubMedCrossRef
75.
Yamamoto T, Kyo M, Kamiya T, Tanaka T, Engel JD, Motohashi H, et al. Predictive base substitution rules that determine the binding and transcriptional specificity of maf recognition elements. Genes Cells. 2006;11(6):575–91.PubMedCrossRef
76.
Li W, Yu S, Liu T, Kim JH, Blank V, Li H, et al. Heterodimerization with small maf proteins enhances nuclear retention of Nrf2 via masking the NESzip motif. Biochim Biophys Acta. 2008;1783(10):1847–56.PubMedPubMedCentralCrossRef
77.
Goldstein LD, Lee J, Gnad F, Klijn C, Schaub A, Reeder J, et al. Recurrent loss of NFE2L2 exon 2 is a mechanism for Nrf2 pathway activation in human cancers. Cell Rep. 2016;16(10):2605–17.PubMedCrossRef
78.
79.
Qiu L, Wang M, Zhu YP, Xiang YC, Zhang YG. A Naturally-Occurring Dominant-Negative inhibitor of Keap1 competitively against its negative regulation of Nrf2. Int J Mol Sci. 2018;19(8):2150.PubMedPubMedCentralCrossRef
80.
Jiang NN, Dai QJ, Su XR, Fu JJ, Feng XC, Peng J. Role of PI3K/AKT pathway in cancer: the framework of malignant behavior. Mol Biol Rep. 2020;47(6):4587–629.PubMedPubMedCentralCrossRef
81.
82.
Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 1998;95(1):29–39.PubMedCrossRef
83.
Brognard J, Sierecki E, Gao TY, Newton AC. PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of akt signaling by regulating distinct akt isoforms. Mol Cell. 2007;25(6):917–31.PubMedCrossRef
84.
Andjelković M, Jakubowicz T, Cron P, Ming XF, Han JW, Hemmings BA. Activation and phosphorylation of a pleckstrin homology domain containing protein kinase (RAC-PK/PKB) promoted by serum and protein phosphatase inhibitors. Proc Natl Acad Sci U S A. 1996;93(12):5699–704.PubMedPubMedCentralCrossRef
85.
LoPiccolo J, Kim SJ, Shi Y, Wu B, Wu HY, Chait BT, et al. Assembly and Molecular Architecture of the phosphoinositide 3-Kinase p85α Homodimer. J Biol Chem. 2015;290(51):30390–405.PubMedPubMedCentralCrossRef
86.
Harpur AG, Layton MJ, Das P, Bottomley MJ, Panayotou G, Driscoll PC, et al. Intermolecular interactions of the p85alpha regulatory subunit of phosphatidylinositol 3-kinase. J Biol Chem. 1999;274(18):12323–32.PubMedCrossRef
87.
Cheung LWT, Walkiewicz KW, Besong TMD, Guo HF, Hawke DH, Arold ST, et al. Regulation of the PI3K pathway through a p85α monomer-homodimer equilibrium. eLife. 2015;4:e06866.PubMedPubMedCentralCrossRef
88.
Abell K, Bilancio A, Clarkson RWE, Tiffen PG, Altaparmakov AI, Burdon TG, et al. Stat3-induced apoptosis requires a molecular switch in PI(3)K subunit composition. Nat Cell Biol. 2005;7(4):392–8.PubMedCrossRef
89.
Lucas CL, Zhang Y, Venida A, Wang Y, Hughes J, McElwee J, et al. Heterozygous splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3K. J Exp Med. 2014;211(13):2537–47.PubMedPubMedCentralCrossRef
90.
Deau MC, Heurtier L, Frange P, Suarez F, Bole-Feysot C, Nitschke P, et al. A human immunodeficiency caused by mutations in the PIK3R1 gene. J Clin Invest. 2014;124(9):3923–8.PubMedPubMedCentralCrossRef
91.
Abolhassani H, Aghamohammadi A, Fang MY, Rezaei N, Jiang CY, Liu X, et al. Clinical implications of systematic phenotyping and exome sequencing in patients with primary antibody deficiency. Genet Med. 2019;21(1):243–51.PubMedCrossRef
92.
Hauck F, Magg T, Krolo A, Bilic I, Hirschmugl T, Laass M, et al. Variant PIK3R1 Hypermorphic Mutation and clinical phenotypes in a family with short statures, mild immunodeficiency and lymphoma. Klin Padiatr. 2017;229(3):113–7.PubMedCrossRef
93.
Olbrich P, Lorenz M, Daball PC, Lucena JM, Rensing-Ehl A, Sanchez B, et al. Activated PI3Kδ syndrome type 2: two patients, a novel mutation, and review of the literature. Pediatr Allergy Immunol. 2016;27(6):640–4.PubMedCrossRef
94.
Lougaris V, Faletra F, Lanzi G, Vozzi D, Marcuzzi A, Valencic E, et al. Altered germinal center reaction and abnormal B cell peripheral maturation in PI3KR1-mutated patients presenting with HIGM-like phenotype. Clin Immunol. 2015;159(1):33–6.PubMedCrossRef
95.
Elkaim E, Neven B, Bruneau J, Mitsui-Sekinaka K, Stanislas A, Heurtier L, et al. Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase delta syndrome 2: a cohort study. J Allergy Clin Immunol. 2016;138(1):210–8.PubMedCrossRef
96.
Breuksch I, Welter J, Bauer HK, Enklaar T, Frees S, Thüroff JW, et al. In renal cell carcinoma the PTEN splice variant PTEN-∆ shows similar function as the tumor suppressor PTEN itself. Cell Commun Signal. 2018;16:35.PubMedPubMedCentralCrossRef
97.
Sharrard RM, Maitland NJ. Alternative splicing of the human PTEN/MMAC1/TEP1 gene. Biochim Biophys Acta. 2000;1494(3):282–5.PubMedCrossRef
98.
Agrawal S, Eng C. Differential expression of novel naturally occurring splice variants of PTEN and their functional consequences in Cowden syndrome and sporadic breast cancer. Hum Mol Genet. 2006;15(5):777–87.PubMedCrossRef
99.
Chen HJ, Romigh T, Sesock K, Eng C. Characterization of cryptic splicing in germline PTEN intronic variants in Cowden syndrome. Hum Mutat. 2017;38(10):1372–7.PubMedPubMedCentralCrossRef
100.
Celebi JT, Wanner M, Ping XL, Zhang H, Peacocke M. Association of splicing defects in PTEN leading to exon skipping or partial intron retention in Cowden syndrome. Hum Genet. 2000;107(3):234–8.PubMedCrossRef
101.
102.
Hartung AM, Swensen J, Uriz IE, Lapin M, Kristjansdottir K, Petersen USS, et al. The splicing efficiency of activating HRAS mutations can determine Costello Syndrome phenotype and frequency in Cancer. PLOS Genet. 2016;12(5):e1006039.PubMedPubMedCentralCrossRef
103.
Pells S, Divjak M, Romanowski P, Impey H, Hawkins NJ, Clarke AR, et al. Developmentally-regulated expression of murine K-ras isoforms. Oncogene. 1997;15(15):1781–6.PubMedCrossRef
104.
Wang Y, You M, Wang Y. Alternative splicing of the K-ras gene in mouse tissues and cell lines. Exp Lung Res. 2001;27(3):255–67.PubMedCrossRef
105.
Laude AJ, Prior IA. Palmitoylation and localisation of RAS isoforms are modulated by the hypervariable linker domain. J Cell Sci. 2008;121(4):421–7.PubMedCrossRef
106.
Tsai FD, Lopes MS, Zhou M, Court H, Ponce O, Fiordalisi JJ, et al. K-Ras4A splice variant is widely expressed in cancer and uses a hybrid membrane-targeting motif. Proc Natl Acad Sci U S A. 2015;112(3):779–84.PubMedPubMedCentralCrossRef
107.
Chen WC, To MD, Westcott PMK, Delrosario R, Kim IJ, Philips M, et al. Targeting KRAS4A splicing through the RBM39/DCAF15 pathway inhibits cancer stem cells. Nat Commun. 2021;12(1):4288.PubMedPubMedCentralCrossRef
108.
Eilertsen IA, Sveen A, Strømme JM, Skotheim RI, Nesbakken A, Lothe RA. Alternative splicing expands the prognostic impact of KRAS in microsatellite stable primary colorectal cancer. Int J Cancer. 2019;144(4):841–7.PubMedCrossRef
109.
Eisfeld AK, Schwind S, Hoag KW, Walker CJ, Liyanarachchi S, Patel R, et al. NRAS isoforms differentially affect downstream pathways, cell growth, and cell transformation. Proc Natl Acad Sci U S A. 2014;111(11):4179–84.PubMedPubMedCentralCrossRef
110.
Endo T. Dominant-negative antagonists of the Ras-ERK pathway: DA-Raf and its related proteins generated by alternative splicing of Raf. Exp Cell Res. 2020;387(2).
111.
Yokoyama T, Takano K, Yoshida A, Katada F, Sun P, Takenawa T, et al. DA-Raf1, a competent intrinsic dominant-negative antagonist of the Ras-ERK pathway, is required for myogenic differentiation. J Cell Biol. 2007;177(5):781–93.PubMedPubMedCentralCrossRef
112.
113.
Uniacke J, Holterman CE, Lachance G, Franovic A, Jacob MD, Fabian MR, et al. An oxygen-regulated switch in the protein synthesis machinery. Nature. 2012;486(7401):126–9.PubMedPubMedCentralCrossRef
114.
Wang Y, Ma M, Xiao XS, Wang ZF. Intronic splicing enhancers, cognate splicing factors and context-dependent regulation rules. Nat Struct Mol Biol. 2012;19(10):1044–52.PubMedPubMedCentralCrossRef
115.
Wang Y, Chen D, Qian HL, Tsai YHS, Shao SJ, Liu QT, et al. The splicing factor RBM4 controls apoptosis, proliferation, and Migration to suppress Tumor Progression. Cancer Cell. 2014;26(3):374–89.PubMedPubMedCentralCrossRef
116.
Wang WY, Quan WL, Yang F, Wei YX, Chen JJ, Yu H, et al. RBM4 modulates the proliferation and expression of inflammatory factors via the alternative splicing of regulatory factors in HeLa cells. Mol Genet Genomics. 2020;295(1):95–106.PubMedCrossRef
117.
Yong HM, Zhao W, Zhou XY, Liu ZY, Tang Q, Shi HC, et al. RNA-Binding motif 4 (RBM4) suppresses Tumor Growth and Metastasis in Human gastric Cancer. Med Sci Monit. 2019;25:4025–34.PubMedPubMedCentralCrossRef
118.
Rbm4-Regulated Alternative Splicing Suppresses Tumorigenesis. Cancer Discov. 2014;4(11):1253.
119.
120.
Anczuków O, Rosenberg AZ, Akerman M, Das S, Zhan LX, Karni R, et al. The splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary epithelial cell transformation. Nat Struct Mol Biol. 2012;19(2):220–8.PubMedPubMedCentralCrossRef
121.
122.
Karni R, de Stanchina E, Lowe SW, Sinha R, Mu D, Krainer AR. The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol. 2007;14(3):185–93.PubMedPubMedCentralCrossRef
123.
Yong HM, Zhu HJ, Zhang S, Zhao W, Wang W, Chen C, et al. Prognostic value of decreased expression of RBM4 in human gastric cancer. Sci Rep. 2016;6:28222.PubMedPubMedCentralCrossRef
124.
Lewis HA, Musunuru K, Jensen KB, Edo C, Chen H, Darnell RB, et al. Sequence-specific RNA binding by a Nova KH domain: implications for paraneoplastic disease and the fragile X syndrome. Cell. 2000;100(3):323–32.PubMedCrossRef
125.
Jensen KB, Dredge BK, Stefani G, Zhong R, Buckanovich RJ, Okano HJ, et al. Nova-1 regulates neuron-specific alternative splicing and is essential for neuronal viability. Neuron. 2000;25(2):359–71.PubMedCrossRef
126.
Buckanovich RJ, Darnell RB. The neuronal RNA binding protein Nova-1 recognizes specific RNA targets in vitro and in vivo. Mol Cell Biol. 1997;17(6):3194–201.PubMedPubMedCentralCrossRef
127.
Raj B, Blencowe BJ. Alternative splicing in the mammalian nervous system: recent insights into mechanisms and functional roles. Neuron. 2015;87(1):14–27.PubMedCrossRef
128.
129.
Buckanovich RJ, Yang YYL, Darnell RB. The onconeural antigen Nova-1 is a neuron-specific RNA-Binding protein, the activity of which is inhibited by paraneoplastic antibodies. J Neurosci. 1996;16(3):1114–22.PubMedPubMedCentralCrossRef
130.
Buckanovich RJ, Posner JB, Darnell RB. Nova, the Paraneoplastic Ri Antigen, is homologous to an rna-binding protein and is specifically expressed in the developing Motor System. Neuron. 1993;11(4):657–72.PubMedCrossRef
131.
Yoon SO, Kim EK, Lee M, Jung WY, Lee H, Kang Y, et al. NOVA1 inhibition by miR-146b-5p in the remnant tissue microenvironment defines occult residual disease after gastric cancer removal. Oncotarget. 2016;7(3):2475–95.PubMedCrossRef
132.
Kim E, Yoon SO, Jung WY, Lee H, Kang Y, Jang YJ, et al. Implications of NOVA1 suppression within the microenvironment of gastric cancer: association with immune cell dysregulation. Gastric Cancer. 2017;20(3):438–47.PubMedCrossRef
133.
Shen B, Zhang Y, Yu SR, Yuan Y, Zhong YJ, Lu JW, et al. MicroRNA-339, an epigenetic modulating target is involved in human gastric carcinogenesis through targeting NOVA1. FEBS Lett. 2015;589(20):3205–11.PubMedCrossRef
134.
Zhi F, Wang Q, Deng DN, Shao NY, Wang R, Xue L, et al. MiR-181b-5p downregulates NOVA1 to suppress Proliferation, Migration and Invasion and promote apoptosis in Astrocytoma. PLoS ONE. 2014;9(10):e109124.PubMedPubMedCentralCrossRef
135.
Zhang YA, Zhu JM, Yin J, Tang WQ, Guo YM, Shen XZ, et al. High expression of neuro-oncological ventral Antigen 1 correlates with poor prognosis in Hepatocellular Carcinoma. PLoS ONE. 2014;9(3):e90955.PubMedPubMedCentralCrossRef
136.
137.
Dredge BK, Darnell RB. Nova regulates GABA(A) receptor gamma2 alternative splicing via a distal downstream UCAU-rich intronic splicing enhancer. Mol Cell Biol. 2003;23(13):4687–700.PubMedPubMedCentralCrossRef
138.
Zhang YA, Liu HN, Zhu JM, Zhang DY, Shen XZ, Liu TT. RNA binding protein Nova1 promotes tumor growth in vivo and its potential mechanism as an oncogene may due to its interaction with GABA(A) receptor-gamma 2. J Biomed Sci. 2016;23:71.PubMedPubMedCentralCrossRef
139.
140.
Ludlow AT, Wong MS, Robin JD, Batten K, Yuan L, Lai TP, et al. NOVA1 regulates hTERT splicing and cell growth in non-small cell lung cancer. Nat Commun. 2018;9:3112.PubMedPubMedCentralCrossRef
141.
Hong YG, Xu GS, Yu GY, Zhou JD, Liu QZ, Ni JS, et al. The RNA binding protein neuro-oncological ventral antigen 1 (NOVA1) regulates IL-6 mRNA stability to enhance JAK2-STAT3 signaling in CRC. Surg Oncol. 2019;31:67–74.PubMedCrossRef
142.
143.
Cretu C, Schmitzová J, Ponce-Salvatierra A, Dybkov O, De Laurentiis EI, Sharma K, et al. Molecular Architecture of SF3b and Structural Consequences of its Cancer-related mutations. Mol Cell. 2016;64(2):307–19.PubMedCrossRef
144.
Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478(7367):64–9.PubMedCrossRef
145.
Song JM, Hussaini M, Qin DH, Zhang XH, Shao HP, Zhang L, et al. Comparison of SF381/DNMT3A comutations with DNMT3A or SF3B1 mutation alone in Myelodysplastic Syndrome and Clonal Cytopenia of undetermined significance. Am J Clin Pathol. 2020;154(1):48–56.PubMedCrossRef
146.
Cazzola M, Rossi M, Malcovati L, Grp AIRC. Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms. Blood. 2013;121(2):260–9.PubMedPubMedCentralCrossRef
147.
148.
Foy A, McMullin MF. Somatic SF3B1 mutations in myelodysplastic syndrome with ring sideroblasts and chronic lymphocytic leukaemia. J Clin Pathol. 2019;72(11):778–82.PubMedCrossRef
149.
150.
Tang AD, Soulette CM, van Baren MJ, Hart K, Hrabeta-Robinson E, Wu CJ, et al. Full-length transcript characterization of SF3B1 mutation in chronic lymphocytic leukemia reveals downregulation of retained introns. Nat Commun. 2020;11(1):1438.PubMedPubMedCentralCrossRef
151.
Yu JF, Li YM, Li T, Li YF, Xing HZ, Sun H, et al. Gene mutational analysis by NGS and its clinical significance in patients with myelodysplastic syndrome and acute myeloid leukemia. Exp Hematol Oncol. 2020;9(1):2.PubMedPubMedCentralCrossRef
152.
153.
Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, Frederick AM, et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature. 2012;486(7403):405–9.PubMedPubMedCentralCrossRef
154.
Ellis MJ, Ding L, Shen D, Luo JQ, Suman VJ, Wallis JW, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353–60.PubMedPubMedCentralCrossRef
155.
156.
Küsters-Vandevelde HVN, Creytens D, van Engen-van Grunsven ACH, Jeunink M, Winnepenninckx V, Groenen PJTA, et al. SF3B1 and EIF1AX mutations occur in primary leptomeningeal melanocytic neoplasms; yet another similarity to uveal melanomas. Acta Neuropathol Commun. 2016;4:5.PubMedPubMedCentralCrossRef
157.
158.
Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 2012;491(7424):399–405.PubMedPubMedCentralCrossRef
159.
Armenia J, Wankowicz SAM, Liu D, Gao JJ, Kundra R, Reznik E, et al. The long tail of oncogenic drivers in prostate cancer. Nat Genet. 2019;51(7):645–51.CrossRef
160.
Damm F, Kosmider O, Gelsi-Boyer V, Renneville A, Carbuccia N, Hidalgo-Curtis N, et al. Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood. 2012;119(14):3211–8.PubMedCrossRef
161.
Patnaik MM, Lasho TL, Hodnefield JM, Knudson RA, Ketterling RP, Al-Kali A, et al. SF3B1 mutations are prevalent in myelodysplastic syndromes with Ring Sideroblasts but do not hold independent Prognostic Value. Blood. 2012;119(2):569–72.PubMedPubMedCentralCrossRef
162.
Bejar R, Stevenson KE, Caughey BA, Abdel-Wahab O, Steensma DP, Galili N, et al. Validation of a Prognostic Model and the impact of mutations in patients with Lower-Risk Myelodysplastic Syndromes. J Clin Oncol. 2012;30(27):3376–82.PubMedPubMedCentralCrossRef
163.
Zhou ZX, Gong Q, Wang Y, Li MK, Wang L, Ding HF, et al. The biological function and clinical significance of SF3B1 mutations in cancer. Biomark Res. 2020;8(1):38.PubMedPubMedCentralCrossRef
164.
Fuentes-Fayos AC, Perez-Gomez JM, G-Garcia ME, Jimenez-Vacas JM, Blanco-Acevedo C, Sanchez-Sanchez R, et al. SF3B1 inhibition disrupts malignancy and prolongs survival in glioblastoma patients through BCL2L1 splicing and mTOR/beta-catenin pathways imbalances. J Exp Clin Cancer Res. 2022;41(1):39.PubMedPubMedCentralCrossRef
165.
López-Cánovas JL, del Rio-Moreno M, García-Fernandez H, Jiménez-Vacas JM, Moreno-Montilla MT, Sánchez-Frias ME, et al. Splicing factor SF3B1 is overexpressed and implicated in the aggressiveness and survival of hepatocellular carcinoma. Cancer Lett. 2021;496:72–83.PubMedCrossRef
166.
Jiménez-Vacas JM, Herrero-Aguayo V, Gómez-Gómez E, León-González AJ, Sáez-Martínez P, Alors-Pérez E, et al. Spliceosome component SF3B1 as novel prognostic biomarker and therapeutic target for prostate cancer. Transl Res. 2019;212:89–103.PubMedCrossRef
167.
Popli P, Richters MM, Chadchan SB, Kim TH, Tycksen E, Griffith O, et al. Splicing factor SF3B1 promotes endometrial cancer progression via regulating KSR2 RNA maturation. Cell Death Dis. 2020;11(10):842.PubMedPubMedCentralCrossRef
168.
Boise LH, González-García M, Postema CE, Ding LY, Lindsten T, Turka LA, et al. Bcl-X, a bcl-2-Related gene that functions as a Dominant Regulator of apoptotic cell-death. Cell. 1993;74(4):597–608.PubMedCrossRef
169.
Trecesson SD, Souaze F, Basseville A, Bernard AC, Pecot J, Lopez J, et al. BCL-X-L directly modulates RAS signalling to favour cancer cell stemness. Nat Commun. 2017;8:1123.CrossRef
170.
Kotake Y, Sagane K, Owa T, Mimori-Kiyosue Y, Shimizu H, Uesugi M, et al. Splicing factor SF3b as a target of the antitumor natural product pladienolide. Nat Chem Biol. 2007;3(9):570–5.PubMedCrossRef
171.
Kaida D, Motoyoshi H, Tashiro E, Nojima T, Hagiwara M, Ishigami K, et al. Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA. Nat Chem Biol. 2007;3(9):576–83.PubMedCrossRef
172.
Hasegawa M, Miura T, Kuzuya K, Inoue A, Ki SW, Horinouchi S, et al. Identification of SAP155 as the target of GEX1A (Herboxidiene), an Antitumor Natural product. ACS Chem Biol. 2011;6(3):229–33.PubMedCrossRef
173.
Xargay-Torrent S, López-Guerra M, Rosich L, Montraveta A, Roldán J, Rodríguez V, et al. The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia. Oncotarget. 2015;6(26):22734–49.PubMedPubMedCentralCrossRef
174.
Seiler M, Yoshimi A, Darman R, Chan B, Keaney G, Thomas M, et al. H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers. Nat Med. 2018;24(4):497–504.PubMedPubMedCentralCrossRef
175.
Steensma DP, Wermke M, Klimek VM, Greenberg PL, Font P, Komrokji RS, et al. Results of a clinical trial of H3B-8800, a Splicing Modulator, in patients with myelodysplastic syndromes (MDS), Acute Myeloid Leukemia (AML) or chronic myelomonocytic leukemia (CMML). Blood. 2019;134:673.CrossRef
176.
Steensma DP, Wermke M, Klimek VM, Greenberg PL, Font P, Komrokji RS, et al. Phase I first-in-human dose escalation study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. Leukemia. 2021;35(12):3542–50.PubMedPubMedCentralCrossRef
177.
Champion-Arnaud P, Reed R. The Prespliceosome Components Sap-49 and Sap-145 interact in a Complex implicated in tethering U2-Snrnp to the Branch Site. Genes Dev. 1994;8(16):1974–83.PubMedCrossRef
178.
179.
Li YW, Diao YC, Wang ZX, Wang SR, Peng JL, Kong BH. The splicing factor SF3B4 drives proliferation and invasion in cervical cancer by regulating SPAG5. Cell Death Discov. 2022;8(1):326.PubMedPubMedCentralCrossRef
180.
He J, Green AR, Li Y, Chan SYT, Liu DX. SPAG5: an emerging Oncogene. Trends Cancer. 2020;6(7):543–7.PubMedCrossRef
181.
Yang YF, Zhang MF, Tian QH, Fu J, Yang X, Zhang CZY, et al. SPAG5 interacts with CEP55 and exerts oncogenic activities via PI3K/AKT pathway in hepatocellular carcinoma. Mol Cancer. 2018;17:117.PubMedPubMedCentralCrossRef
182.
Liu HL, Hu JW, Wei R, Zhou LF, Pan H, Zhu HC, et al. SPAG5 promotes hepatocellular carcinoma progression by downregulating SCARA5 through modifying beta-catenin degradation. J Exp Clin Cancer Res. 2018;37:229.PubMedPubMedCentralCrossRef
183.
Li M, Li AQ, Zhou SL, Lv H, Yang WT. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer. J Hematol Oncol. 2019;12:14.PubMedPubMedCentralCrossRef
184.
Canu V, Donzelli S, Sacconi A, Lo Sardo F, Pulito C, Bossel N, et al. Aberrant transcriptional and post-transcriptional regulation of SPAG5, a YAP-TAZ-TEAD downstream effector, fuels breast cancer cell proliferation. Cell Death Differ. 2021;28(5):1493–511.PubMedCrossRef
185.
Wong YH, Wu CC, Lin CL, Chen TS, Chang TH, Chen BS. Applying NGS data to find Evolutionary Network biomarkers from the early and late stages of Hepatocellular Carcinoma. BioMed Res Int. 2015;2015:2015.CrossRef
186.
Xu WJ, Huang HX, Yu L, Cao LH. Meta-analysis of gene expression profiles indicates genes in spliceosome pathway are up-regulated in hepatocellular carcinoma (HCC). Med Oncol. 2015;32(4):96.PubMedCrossRef
187.
Iguchi T, Komatsu H, Masuda T, Nambara S, Kidogami S, Ogawa Y, et al. Increased Copy Number of the Gene Encoding SF3B4 indicates poor prognosis in Hepatocellular Carcinoma. Anticancer Res. 2016;36(5):2139–44.PubMed
188.
Shen Q, Eun JW, Lee K, Kim HS, Yang HD, Kim SY, et al. Barrier to autointegration factor 1, procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3, and splicing factor 3b subunit 4 as early-stage cancer decision markers and drivers of hepatocellular carcinoma. Hepatology. 2018;67(4):1360–77.PubMedCrossRef
189.
Bernier FP, Caluseriu O, Ng S, Schwartzentruber J, Buckingham KJ, Innes AM, et al. Haploinsufficiency of SF3B4, a component of the Pre-mRNA Spliceosomal Complex, causes Nager Syndrome. Am J Hum Genet. 2012;90(5):925–33.PubMedPubMedCentralCrossRef
190.
McPherson E, Zaleski C, Ye Z, Lin S. Rodriguez syndrome with SF3B4 mutation: a severe form of Nager syndrome? Am J Med Genet A. 2014;164(7):1841–5.CrossRef
191.
Devotta A, Juraver-Geslin H, Gonzalez JA, Hong CS, Saint-Jeannet JP. Sf3b4-depleted Xenopus embryos: a model to study the pathogenesis of craniofacial defects in Nager syndrome. Dev Biol. 2016;415(2):371–82.PubMedPubMedCentralCrossRef
192.
Marques F, Tenney J, Duran I, Martin J, Nevarez L, Pogue R, et al. Altered mRNA splicing, Chondrocyte Gene expression and abnormal skeletal development due to SF3B4 mutations in Rodriguez Acrofacial Dysostosis. PLOS Genet. 2016;12(9):e1006307.PubMedPubMedCentralCrossRef
193.
Diao YC, Li YW, Wang ZX, Wang SR, Li P, Kong BH. SF3B4 promotes ovarian cancer progression by regulating alternative splicing of RAD52. Cell Death Dis. 2022;13(2):179.PubMedPubMedCentralCrossRef
194.
Li P, Xu YZ, Zhang QL, Li Y, Jia WX, Wang X, et al. Evaluating the role of RAD52 and its interactors as novel potential molecular targets for hepatocellular carcinoma. Cancer Cell Int. 2019;19(1):279.PubMedPubMedCentralCrossRef
195.
Lieberman R, Xiong DH, James M, Han YH, Amos CI, Wang L, et al. Functional characterization of RAD52 as a lung cancer susceptibility gene in the 12p13.33 locus. Mol Carcinog. 2016;55(5):953–63.PubMedCrossRef
196.
Toma M, Sullivan-Reed K, Śliwiński T, Skorski T. RAD52 as a potential target for synthetic lethality-based Anticancer Therapies. Cancers. 2019;11(10):1561.PubMedPubMedCentralCrossRef
197.
Kidogami S, Iguchi T, Sato K, Yoshikawa Y, Hu Q, Nambara S, et al. SF3B4 plays an oncogenic role in esophageal squamous cell carcinoma. Anticancer Res. 2020;40(5):2941–6.PubMedCrossRef
198.
Zhou WT, Ma N, Jiang H, Rong YF, Deng YZ, Feng YY, et al. SF3B4 is decreased in pancreatic cancer and inhibits the growth and migration of cancer cells. Tumour Biol. 2017;39(3):1010428317695913.PubMedCrossRef
199.
200.
201.
Xiong J, Chen YS, Wang WP, Sun J. Biological function and molecular mechanism of SRSF3 in cancer and beyond. Oncol Lett. 2022;23(1):21.PubMedCrossRef
202.
Huang YQ, Steitz JA. Splicing factors SRp20 and 9G8 promote the nucleocytoplasmic export of mRNA. Mol Cell. 2001;7(4):899–905.PubMedCrossRef
203.
Park SK, Jeong S. SRSF3 represses the expression of PDCD4 protein by coordinated regulation of alternative splicing, export and translation. Biochem Biophys Res Commun. 2016;470(2):431–8.PubMedCrossRef
204.
Ratnadiwakara M, Archer SK, Dent CI, De Los Mozos IR, Beilharz TH, Knaupp AS, et al. SRSF3 promotes pluripotency through nanog mRNA export and coordination of the pluripotency gene expression program. eLife. 2018;7:e37419.PubMedPubMedCentralCrossRef
205.
206.
Maciolek NL, McNally MT. Serine/arginine-Rich proteins contribute to negative regulator of splicing element-stimulated polyadenylation in rous sarcoma virus. J Virol. 2007;81(20):11208–17.PubMedPubMedCentralCrossRef
207.
Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst. 2006;98(4):262–72.PubMedCrossRef
208.
Schmidt M, Böhm D, von Törne C, Steiner E, Puhl A, Pilch H, et al. The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res. 2008;68(13):5405–13.PubMedCrossRef
209.
Ke H, Zhao LM, Zhang HL, Feng X, Xu HB, Hao JJ, et al. Loss of TDP43 inhibits progression of triple-negative breast cancer in coordination with SRSF3. Proc Natl Acad Sci U S A. 2018;115(15):E3426–35.PubMedPubMedCentralCrossRef
210.
Su YA, Yang J, Tao L, Nguyen H, He P. Undetectable and decreased expression of KIAA1949 (phostensin) encoded on chromosome 6p21.33 in human breast cancers revealed by Transcriptome Analysis. J Cancer. 2010;1:38–50.PubMedPubMedCentralCrossRef
211.
Kim YJ, Kim BR, Ryu JS, Lee GO, Kim HR, Choi KH, et al. HNRNPA1, a Splicing Regulator, is an effective target protein for cervical Cancer detection comparison with conventional tumor markers. Int J Gynecol Cancer. 2017;27(2):326–31.PubMedCrossRef
212.
Torres S, García-Palmero I, Marín-Vicente C, Bartolomé RA, Calviño E, Fernández-Aceñero MJ, et al. Proteomic characterization of transcription and splicing factors Associated with a metastatic phenotype in Colorectal Cancer. J Proteome Res. 2018;17(1):252–64.PubMedCrossRef
213.
Kuranaga Y, Sugito N, Shinohara H, Tsujino T, Taniguchi K, Komura K, et al. SRSF3, a Splicer of the PKM Gene, regulates cell growth and maintenance of Cancer-Specific Energy metabolism in Colon Cancer cells. Int J Mol Sci. 2018;19(10):3012.PubMedPubMedCentralCrossRef
214.
Kurokawa K, Akaike Y, Masuda K, Kuwano Y, Nishida K, Yamagishi N, et al. Downregulation of serine/arginine-rich splicing factor 3 induces G1 cell cycle arrest and apoptosis in colon cancer cells. Oncogene. 2014;33(11):1407–17.PubMedCrossRef
215.
Song X, Wan XC, Huang TZ, Zeng C, Sastry N, Wu BL, et al. SRSF3-Regulated RNA alternative splicing promotes Glioblastoma Tumorigenicity by affecting multiple Cellular processes. Cancer Res. 2019;79(20):5288–301.PubMedPubMedCentralCrossRef
216.
Xu LF, Shen JX, Jia J, Jia R. Inclusion of hnRNP L alternative exon 7 is Associated with Good Prognosis and inhibited by Oncogene SRSF3 in Head and Neck squamous cell carcinoma. BioMed Res Int. 2019;2019:2019.CrossRef
217.
Wang HL, Lekbaby B, Fares N, Augustin J, Attout T, Schnuriger A, et al. Alteration of splicing factors’ expression during liver disease progression: impact on hepatocellular carcinoma outcome. Hepatol Int. 2019;13(4):454–67.PubMedCrossRef
218.
Chen H, Gao F, He M, Ding XF, Wong AM, Sze SC, et al. Long-read RNA sequencing identifies alternative splice variants in Hepatocellular Carcinoma and Tumor-Specific Isoforms. Hepatology. 2019;70(3):1011–25.PubMedCrossRef
219.
Yea S, Narla G, Zhao X, Garg R, Tal-Kremer S, Hod E, et al. Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma. Gastroenterology. 2008;134(5):1521–31.PubMedCrossRef
220.
Jia R, Zhang S, Liu MM, Zhang Y, Liu Y, Fan MW, et al. HnRNP L is important for the expression of oncogene SRSF3 and oncogenic potential of oral squamous cell carcinoma cells. Sci Rep. 2016;6:35976.PubMedPubMedCentralCrossRef
221.
Liu PQ, Guo ZZ, Yin YT, Jia J, Guo JH, Jia R. Expression of SRSF3 is correlated with carcinogenesis and progression of oral squamous cell carcinoma. Int J Med Sci. 2016;13(7):533–9.CrossRef
222.
He XL, Ee PLR, Coon JS, Beck WT. Alternative splicing of the multidrug resistance protein 1/ATP binding cassette transporter subfamily gene in ovarian cancer creates functional splice variants and is associated with increased expression of the splicing factors PTB and SRp20. Clin Cancer Res. 2004;10(14):4652–60.PubMedCrossRef
223.
Iborra S, Hirschfeld M, Jaeger M, zur Hausen A, Braicu I, Sehouli J, et al. Alterations in expression pattern of splicing factors in epithelial ovarian Cancer and its clinical impact. Int J Gynecol Cancer. 2013;23(6):990–6.PubMedCrossRef
224.
Villegas VM, Gold AS, Wildner A, Ehlies F, Murray TG. Genomic landscape of retinoblastoma. Clin Exp Ophthalmol. 2014;42(1):2–3.PubMedCrossRef
225.
Kooi IE, Mol BM, Massink MPG, de Jong MC, de Graaf P, van der Valk P, et al. A Meta-analysis of Retinoblastoma Copy numbers refines the list of possible driver genes involved in Tumor Progression. PLoS ONE. 2016;11(4):e0153323.PubMedPubMedCentralCrossRef
226.
Lankat-Buttgereit B, Göke R. The tumour suppressor Pdcd4: recent advances in the elucidation of function and regulation. Biol Cell. 2009;101(6):309–17.PubMedCrossRef
227.
Kim J, Park RY, Chen JK, Kim J, Jeong S, Ohn T. Splicing factor SRSF3 represses the translation of programmed cell death 4 mRNA by associating with the 5’-UTR region. Cell Death Differ. 2014;21(3):481–90.PubMedCrossRef
228.
Danovi D, Meulmeester E, Pasini D, Migliorini D, Capra M, Frenk R, et al. Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity. Mol Cell Biol. 2004;24(13):5835–43.PubMedPubMedCentralCrossRef
229.
230.
Dewaele M, Tabaglio T, Willekens K, Bezzi M, Teo SX, Low DHP, et al. Antisense oligonucleotide-mediated MDM4 exon 6 skipping impairs tumor growth. J Clin Invest. 2016;126(1):68–84.PubMedCrossRef
231.
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, Mcguire WL. Human-breast Cancer - correlation of Relapse and Survival with amplification of the Her-2 Neu Oncogene. Science. 1987;235(4785):177–82.PubMedCrossRef
232.
Gautrey H, Jackson C, Dittrich AL, Browell D, Lennard T, Tyson-Capper A. SRSF3 and hnRNP H1 regulate a splicing hotspot of HER2 in breast cancer cells. RNA Biol. 2015;12(10):1139–51.PubMedPubMedCentralCrossRef
233.
Aigner A, Juhl H, Malerczyk C, Tkybusch A, Benz CC, Czubayko F. Expression of a truncated 100 kDa HER2 splice variant acts as an endogenous inhibitor of tumour cell proliferation. Oncogene. 2001;20(17):2101–11.PubMedCrossRef
234.
Romanelli MG, Diani E, Lievens PMJ. New Insights into functional roles of the polypyrimidine tract-binding protein. Int J Mol Sci. 2013;14(11):22906–32.PubMedPubMedCentralCrossRef
235.
Sawicka K, Bushell M, Spriggs KA, Willis AE. Polypyrimidine-tract-binding protein: a multifunctional RNA-binding protein. Biochem Soc Trans. 2008;36:641–7.PubMedCrossRef
236.
Ray D, Kazan H, Chan ET, Castillo LP, Chaudhry S, Talukder S, et al. Rapid and systematic analysis of the RNA recognition specificities of RNA-binding proteins. Nat Biotechnol. 2009;27(7):667–70.PubMedCrossRef
237.
Reid DC, Chang BL, Gunderson SI, Alpert L, Thompson WA, Fairbrother WG. Next-generation SELEX identifies sequence and structural determinants of splicing factor binding in human pre-mRNA sequence. RNA. 2009;15(12):2385–97.PubMedPubMedCentralCrossRef
238.
He X, Arslan AD, Pool MD, Ho TT, Darcy KM, Coon JS, et al. Knockdown of splicing factor SRp20 causes apoptosis in ovarian cancer cells and its expression is associated with malignancy of epithelial ovarian cancer. Oncogene. 2011;30(3):356–65.PubMedCrossRef
239.
Wang C, Norton JT, Ghosh S, Kim J, Fushimi K, Wu JY, et al. Polypyrimidine tract-binding protein (PTB) differentially affects malignancy in a cell line-dependent manner. J Biol Chem. 2008;283(29):20277–87.PubMedPubMedCentralCrossRef
240.
He X, Pool M, Darcy KM, Lim SB, Auersperg N, Coon JS, et al. Knockdown of polypyrimidine tract-binding protein suppresses ovarian tumor cell growth and invasiveness in vitro. Oncogene. 2007;26(34):4961–8.PubMedPubMedCentralCrossRef
241.
Cheung HC, Hai T, Zhu W, Baggerly KA, Tsavachidis S, Krahe R, et al. Splicing factors PTBP1 and PTBP2 promote proliferation and migration of glioma cell lines. Brain. 2009;132:2277–88.PubMedPubMedCentralCrossRef
242.
Izaguirre DI, Zhu W, Hai T, Cheung HC, Krahe R, Cote GJ. PTBP1-Dependent regulation of USP5 Alternative RNA splicing plays a role in Glioblastoma Tumorigenesis. Mol Carcinog. 2012;51(11):895–906.PubMedCrossRef
243.
Qu M, Song N, Chai G, Wu XL, Liu W. Pathological niche environment transforms dermal stem cells to keloid stem cells: a hypothesis of keloid formation and development. Med Hypotheses. 2013;81(5):807–12.PubMedCrossRef
244.
Appleton I, Brown NJ, Willoughby DA. Apoptosis, necrosis, and proliferation - possible implications in etiology of keloids. Am J Pathol. 1996;149(5):1441–7.PubMedPubMedCentral
245.
Jiao H, Dong P, Yan L, Yang ZG, Lv XY, Li QC, et al. TGF-β1 induces polypyrimidine tract-binding protein to alter fibroblasts proliferation and fibronectin deposition in Keloid. Sci Rep. 2016;6:38033.PubMedPubMedCentralCrossRef
246.
Jin W, Bruno IG, Xie TX, Sanger LJ, Cote GJ. Polypyrimidine tract-binding protein down-regulates fibroblast growth factor receptor 1 alpha-exon inclusion. Cancer Res. 2003;63(19):6154–7.PubMed
247.
Carstens RP, Wagner EJ, Garcia-Blanco MA. An intronic splicing silencer causes skipping of the IIIb exon of fibroblast growth factor receptor 2 through involvement of polypyrimidine tract binding protein. Mol Cell Biol. 2000;20(19):7388–400.PubMedPubMedCentralCrossRef
248.
Côté J, Dupuis S, Wu JY. Polypyrimidine track-binding protein binding downstream of caspase-2 alternative exon 9 represses its inclusion. J Biol Chem. 2001;276(11):8535–43.PubMedCrossRef
249.
Izquierdo JM. Hu antigen R (HuR) functions as an alternative pre-mRNA splicing regulator of Fas apoptosis-promoting receptor on exon definition. J Biol Chem. 2008;283(27):19077–84.PubMedCrossRef
250.
Izquierdo JM, Majós N, Bonnal S, Martínez C, Castelo R, Guigó R, et al. Regulation of fas alternative splicing by antagonistic effects of TIA-1 and PTB on exon definition. Mol Cell. 2005;19(4):475–84.PubMedCrossRef
251.
Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 2008;452(7184):230–43.PubMedCrossRef
252.
David CJ, Chen M, Assanah M, Canoll P, Manley JL. HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature. 2010;463(7279):364–8.PubMedCrossRef
253.
Calabretta S, Bielli P, Passacantilli I, Pilozzi E, Fendrich V, Capurso G, et al. Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells. Oncogene. 2016;35(16):2031–9.PubMedCrossRef
254.
Glinos DA, Garborcauskas G, Hoffman P, Ehsan N, Jiang LH, Gokden A, et al. Transcriptome variation in human tissues revealed by long-read sequencing. Nature. 2022;608(7922):353–9.PubMedPubMedCentralCrossRef
255.
Gao DD, Morini E, Salani M, Krauson AJ, Chekuri A, Sharma N, et al. A deep learning approach to identify gene targets of a therapeutic for human splicing disorders. Nat Commun. 2021;12(1):3332.PubMedPubMedCentralCrossRef
Metadata
Title
The role of alternative pre-mRNA splicing in cancer progression
Authors
Sunkyung Choi
Namjoon Cho
Eun-Mi Kim
Kee K. Kim
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2023
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-023-03094-3

Other articles of this Issue 1/2023

Cancer Cell International 1/2023 Go to the issue

Review

A review on the role of long non-coding RNA and microRNA network in clear cell renal cell carcinoma and its tumor microenvironment

Research

Statins enhances antitumor effect of oxaliplatin in KRAS-mutated colorectal cancer cells and inhibits oxaliplatin-induced neuropathy

Review

Single-cell RNA sequencing in cancer research: discovering novel biomarkers and therapeutic targets for immune checkpoint blockade

Review

Enhancing HCC Treatment: innovatively combining HDAC2 inhibitor with PD-1/PD-L1 inhibition

Research

Changes in HER3 expression profiles between primary and recurrent gynecological cancers

Research

Prediction model for hyperprogressive disease in patients with advanced solid tumors received immune-checkpoint inhibitors: a pan-cancer study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits